CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
Active, not recruiting · Phase 2 · NCT05440786
Conditions: Sarcoma, Ewing, Neoplasm Metastasis
At a glance
- Research payments reported, 2025
- $148,512
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 46
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Abemaciclib (drug), Irinotecan (drug), Temozolomide (drug)
- Dates
- Started 2022-09-20; completion 2027-12
- Results posted
- Yes
The purpose of this study is to measure the benefit of adding abemaciclib to chemotherapy (irinotecan and temozolomide) for Ewing's sarcoma that has come back or did not respond to treatment. This trial is part of the CAMPFIRE master protocol, which is a platform to speed development of new treatments for children and young adults with cancer. Your participation in this trial could last 11 months or longer, depending on how you and your tumor respond.
From ClinicalTrials.gov, last updated 2026-10-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $148,512 in research payments for this study in 2025 (4 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Alok K. Kothari, MD Pediatric Hematology & Oncology · Phoenix, AZ
- Marissa Just, M.D. Pediatric Hematology & Oncology · Indianapolis, IN
- Bradley D. Denardo, MD Pediatric Hematology & Oncology · Providence, RI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Indiana University $124,849
- Rhode Island Hospital, RI $19,142
- Phoenix Children's Hospital, AZ $4,521
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.